Erythropoietin reduces brain injury after intracerebral hemorrhagic stroke in rats

Yu,Zhen; Tang,Ling; Chen,Lifen; Li,Jinfang; Wu,Wanfu; Hu,Changlin

doi:10.3892/mmr.2013.1666

Erythropoietin reduces brain injury after intracerebral hemorrhagic stroke in rats

Authors:
- Zhen Yu
- Ling Tang
- Lifen Chen
- Jinfang Li
- Wanfu Wu
- Changlin Hu
View Affiliations

Affiliations: Department of Neurology, The Second Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400010, P.R. China, Department of Neurology, The Fifth Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400010, P.R. China, Department of Neurology, The First Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400010, P.R. China
Published online on: September 4, 2013 https://doi.org/10.3892/mmr.2013.1666
Pages: 1315-1322

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Erythropoietin (EPO) has been shown to be neuroprotective in various models of neuronal injury. The aim of the present study was to investigate the beneficial effect of recombinant human EPO (rhEPO) following intracerebral hemorrhage (ICH) and the underlying molecular and cellular mechanisms. ICH was induced using autologous blood injection in adult rats. rhEPO (5000 IU/kg) or vehicle was administered to rats with ICH 2 h following surgery and every 24 h for 1 or 3 days. To study the involvement of the PI3K signaling pathway in the rhEPO‑mediated effect, the PI3K inhibitor wortmannin (15 µg/kg), was intravenously administered to rats with ICH 90 min prior to rhEPO treatment. Brain edema was measured 3 days following ICH and behavioral outcomes were measured at 1, 7, 14, 21 and 28 days following ICH using the modified neurological severity score (mNSS) and the corner turn test. Proinflammatory cytokines, including tumor necrosis factor (TNF)‑α, interleukin (IL)‑1β and IL‑6, in the ipsilateral striatum were analyzed using an enzyme‑linked immunosorbent assay 24 h following ICH. Neuronal apoptosis in the perihematomal area was determined by NeuN and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) double‑staining. The results showed that rhEPO treatment reversed ICH, increased brain water content, upregulated proinflammatory cytokines, neuronal loss and apoptosis in the perihematomal area and rescued behavioral deficits in injured rats. Inhibiting the PI3K pathway with wortmannin abolished the rhEPO‑mediated neuroprotective effects. Moreover, western blot analysis showed that rhEPO induced the upregulation of Akt phosphorylation and downregulation of glycogen synthase kinase (GSK)‑3β phosphorylation, which were reversed by pretreatment with wortmannin, indicating the involvement of PI3K signaling in rhEPO-mediated anti‑apoptotic and anti‑inflammatory effects following ICH. In conclusion, these results suggested that rhEPO may exert its beneficial effects in ICH through the activation of the PI3K signaling pathway.

View Figures

View References

1	Ostrowski RP, Colohan AR and Zhang JH: Mechanisms of hyperbaric oxygen-induced neuroprotection in a rat model of subarachnoid hemorrhage. J Cereb Blood Flow Metab. 25:554–571. 2005. View Article : Google Scholar : PubMed/NCBI
2	Lyden PD and Zivin JA: Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev. 5:1–16. 1993.PubMed/NCBI
3	Zeng JS, Zheng P, Xu JF, et al: Prediction of motor function by diffusion tensor tractography in patients with basal ganglion haemorrhage. Arch Med Sci. 7:310–314. 2011. View Article : Google Scholar : PubMed/NCBI
4	Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, et al: Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 38:2001–2023. 2007.
5	Daverat P, Castel JP, Dartigues JF and Orgogozo JM: Death and functional outcome after spontaneous intracerebral hemorrhage. A prospective study of 166 cases using multivariate analysis. Stroke. 22:1–6. 1991. View Article : Google Scholar
6	Cotena S, Piazza O and Tufano R: The use of erythropoietin in cerebral diseases. Panminerva Med. 50:185–192. 2008.PubMed/NCBI
7	Li L, Jiang Q, Ding G, et al: MRI identification of white matter reorganization enhanced by erythropoietin treatment in a rat model of focal ischemia. Stroke. 40:936–941. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ruscher K, Freyer D, Karsch M, et al: Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci. 22:10291–10301. 2002.PubMed/NCBI
9	Sirén AL, Fratelli M, Brines M, et al: Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA. 98:4044–4049. 2001.PubMed/NCBI
10	Celik M, Gökmen N, Erbayraktar S, et al: Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA. 99:2258–2263. 2002. View Article : Google Scholar : PubMed/NCBI
11	Hwang J, Huh J, Kim J, Jeon Y, Cho S and Han S: Pretreatment with erythropoietin attenuates the neurological injury after spinal cord ischaemia. Spinal Cord. 50:208–212. 2012. View Article : Google Scholar : PubMed/NCBI
12	Xiong Y, Mahmood A, Meng Y, Zhang Y, Qu C, Schallert T and Chopp M: Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose. J Neurosurg. 113:598–608. 2010. View Article : Google Scholar
13	Xiong Y, Mahmood A, Lu D, et al: Histological and functional outcomes after traumatic brain injury in mice null for the erythropoietin receptor in the central nervous system. Brain Res. 1230:247–257. 2008. View Article : Google Scholar : PubMed/NCBI
14	Chen G, Zhang S, Shi J, Ai J and Hang C: Effects of recombinant human erythropoietin (rhEPO) on JAK2/STAT3 pathway and endothelial apoptosis in the rabbit basilar artery after subarachnoid hemorrhage. Cytokine. 45:162–168. 2009. View Article : Google Scholar
15	Grasso G, Buemi M, Alafaci C, et al: Beneficial effects of sys- temic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci USA. 99:5627–5631. 2002. View Article : Google Scholar
16	Tseng MY, Hutchinson PJ, Richards HK, et al: Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. J Neurosurg. 111:171–180. 2009. View Article : Google Scholar
17	Chau M, Chen D and Wei L: Erythropoietin attenuates inflammatory factors and cell death in neonatal rats with intracerebral hemorrhage. Acta Neurochir Suppl. 111:299–305. 2011. View Article : Google Scholar : PubMed/NCBI
18	Seyfried DM, Han Y, Yang D, Ding J and Chopp M: Erythropoietin promotes neurological recovery after intracerebral hemorrhage in rats. Int J Stroke. 4:250–256. 2009. View Article : Google Scholar : PubMed/NCBI
19	Grasso G, Graziano F, Sfacteria A, et al: Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage. Neurosurgery. 65:763–770. 2009. View Article : Google Scholar : PubMed/NCBI
20	Lee ST, Chu K, Sinn DI, et al: Erythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhage. J Neurochem. 96:1728–1739. 2006. View Article : Google Scholar : PubMed/NCBI
21	Seyfried D, Han Y, Lu D, Chen J, Bydon A and Chopp M: Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg. 101:104–107. 2004. View Article : Google Scholar
22	Duris K, Manaenko A, Suzuki H, Rolland WB, Krafft PR and Zhang JH: α7 nicotinic acetylcholine receptor agonist pnu-282987 attenuates early brain injury in a perforation model of subarachnoid hemorrhage in rats. Stroke. 42:3530–3536. 2011.
23	Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, et al: Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. J Med Chem. 49:4425–4436. 2006.
24	Aronowski J and Hall CE: New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies. Neurol Res. 27:268–279. 2005. View Article : Google Scholar : PubMed/NCBI
25	Chen J, Li Y, Wang L, et al: Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 32:1005–1011. 2001. View Article : Google Scholar : PubMed/NCBI
26	Ma Q, Manaenko A, Khatibi NH, Chen W, Zhang JH and Tang J: Vascular adhesion protein-1 inhibition provides antiinflammatory protection after an intracerebral hemorrhagic stroke in mice. J Cereb Blood Flow Metab. 31:881–893. 2011. View Article : Google Scholar
27	Del Bigio MR, Yan HJ, Buist R and Peeling J: Experimental intracerebral hemorrhage in rats. Magnetic resonance imaging and histopathological correlates. Stroke. 27:2312–2319. 1996.PubMed/NCBI
28	van der Kooij MA, Groenendaal F, Kavelaars A, et al: Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res Rev. 59:22–33. 2008.PubMed/NCBI
29	Loftspring MC, McDole J, Lu A, Clark JF and Johnson AJ: Intracerebral hemorrhage leads to infiltration of several leukocyte populations with concomitant pathophysiological changes. J Cereb Blood Flow Metab. 29:137–143. 2009. View Article : Google Scholar
30	Wang J: Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog Neurobiol. 92:463–477. 2010. View Article : Google Scholar : PubMed/NCBI
31	Hanisch UK: Microglia as a source and target of cytokines. Glia. 40:140–155. 2002.PubMed/NCBI
32	Allan SM and Rothwell NJ: Cytokines and acute neurodegeneration. Nat Rev Neurosci. 2:734–744. 2001. View Article : Google Scholar : PubMed/NCBI
33	Masada T, Hua Y, Xi G, Yang GY, Hoff JT and Keep RF: Attenuation of intracerebral hemorrhage and thrombin-induced brain edema by overexpression of interleukin-1 receptor antagonist. J Neurosurg. 95:680–686. 2001. View Article : Google Scholar
34	Xi G, Keep RF and Hoff JT: Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 5:53–63. 2006. View Article : Google Scholar : PubMed/NCBI
35	Zazulia AR, Diringer MN, Derdeyn CP and Powers WJ: Progression of mass effect after intracerebral hemorrhage. Stroke. 30:1167–1173. 1999. View Article : Google Scholar : PubMed/NCBI
36	Jung KH, Chu K, Jeong SW, et al: HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke. 35:1744–1749. 2004. View Article : Google Scholar
37	Villa P, Bigini P, Mennini T, Agnello D, et al: Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med. 198:971–975. 2003. View Article : Google Scholar
38	Liu X, Shen J, Jin Y, Duan M and Xu J: Recombinant human erythropoietin (rhEPO) preconditioning on nuclear factor-kappa B (NF-kB) activation & proinflammatory cytokines induced by myocardial ischaemia-reperfusion. Indian J Med Res. 124:343–354. 2006.
39	Belayev L, Khoutorova L, Zhao W, et al: Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats. Stroke. 36:1071–1076. 2005. View Article : Google Scholar : PubMed/NCBI
40	Brines ML, Ghezzi P, Keenan S, et al: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 97:10526–10531. 2000. View Article : Google Scholar : PubMed/NCBI
41	Valerio A, Bertolotti P, Delbarba A, et al: Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production. J Neurochem. 116:1148–1159. 2011. View Article : Google Scholar
42	Yano S, Morioka M, Fukunaga K, et al: Activation of Akt/protein kinase B contributes to induction of ischemic tolerance in the CA1 subfield of gerbil hippocampus. J Cereb Blood Flow Metab. 21:351–360. 2001. View Article : Google Scholar : PubMed/NCBI